MISSISSAUGA, ON, May 16, 2018 /CNW/ - Effective May 15, 2018, the previously announced acquisitionby Cipher Pharmaceuticals Inc. ("Cipher") of the Canadian business portfolio of Cardiome Pharma Corp. ("Cardiome") was completed by way of the acquisition by Cipher of all of the issued and outstanding common shares of Cardiome ("Common Shares
Under the Arrangement, Cipher acquired ownership and control of an aggregate of 34,871,471 Common Shares (the "Acquisition"), representing 100% of the issued and outstanding Common Shares, at a deemed price of approximately $0.73 per Common Share for aggregate cash consideration of $25,500,000. Immediately prior to the completion of the Acquisition, Cipher did not hold any Common Shares.
The purpose of the Acquisition was to enable Cipher to acquire the Canadian business portfolio of Cardiome by way of the acquisition of all of the issued and outstanding Common Shares.
This news release is being issued in accordance with National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues in connection with the filing of an early warning report dated May 16, 2018 on the System for Electronic Document Analysis and Review ("SEDAR") under Cardiome's issuer profile at www.sedar.com.
SOURCE Cipher Pharmaceuticals Inc.
Subscribe to our Free Newsletters!
Osteolysis refers to breaking down of bone tissue. Bone loss occurs due to resorption of bone by ...
Patisiran injection, recently approved by FDA to treat polyneuropathy, a disease that causes ...
Dysgraphia or disorder of written expression is a childhood learning disorder marked by poor ...View All